812 related articles for article (PubMed ID: 12124352)
1. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL
Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352
[TBL] [Abstract][Full Text] [Related]
2. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
[TBL] [Abstract][Full Text] [Related]
3. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
[TBL] [Abstract][Full Text] [Related]
4. The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression.
Cappellini A; Tabellini G; Zweyer M; Bortul R; Tazzari PL; Billi AM; Falà F; Cocco L; Martelli AM
Leukemia; 2003 Nov; 17(11):2157-67. PubMed ID: 12931221
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.
Marches R; Uhr JW
Int J Cancer; 2004 Nov; 112(3):492-501. PubMed ID: 15382077
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
7. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
8. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
9. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.
Narita Y; Nagane M; Mishima K; Huang HJ; Furnari FB; Cavenee WK
Cancer Res; 2002 Nov; 62(22):6764-9. PubMed ID: 12438278
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.
Viglietto G; Motti ML; Bruni P; Melillo RM; D'Alessio A; Califano D; Vinci F; Chiappetta G; Tsichlis P; Bellacosa A; Fusco A; Santoro M
Nat Med; 2002 Oct; 8(10):1136-44. PubMed ID: 12244303
[TBL] [Abstract][Full Text] [Related]
12. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
13. Development of Herceptin resistance in breast cancer cells.
Kute T; Lack CM; Willingham M; Bishwokama B; Williams H; Barrett K; Mitchell T; Vaughn JP
Cytometry A; 2004 Feb; 57(2):86-93. PubMed ID: 14750129
[TBL] [Abstract][Full Text] [Related]
14. Cytokine-induced phosphoinositide 3-kinase activity promotes Cdk2 activation in factor-dependent hematopoietic cells.
Henry MK; Nimbalkar D; Hohl RJ; Quelle FW
Exp Cell Res; 2004 Sep; 299(1):257-66. PubMed ID: 15302592
[TBL] [Abstract][Full Text] [Related]
15. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Moasser MM; Basso A; Averbuch SD; Rosen N
Cancer Res; 2001 Oct; 61(19):7184-8. PubMed ID: 11585753
[TBL] [Abstract][Full Text] [Related]
16. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
[TBL] [Abstract][Full Text] [Related]
17. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
[TBL] [Abstract][Full Text] [Related]
18. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest.
Liang J; Zubovitz J; Petrocelli T; Kotchetkov R; Connor MK; Han K; Lee JH; Ciarallo S; Catzavelos C; Beniston R; Franssen E; Slingerland JM
Nat Med; 2002 Oct; 8(10):1153-60. PubMed ID: 12244302
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.
Lu Y; Zi X; Pollak M
Int J Cancer; 2004 Jan; 108(3):334-41. PubMed ID: 14648698
[TBL] [Abstract][Full Text] [Related]
20. HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis.
Dubská L; Andera L; Sheard MA
FEBS Lett; 2005 Aug; 579(19):4149-58. PubMed ID: 16023111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
